UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of March, 2014
Commission File Number:
000-51310
XTL Biopharmaceuticals
Ltd.
(Translation of registrant’s name
into English)
85 Medinat Hayehudim St., Herzliya
Pituach, PO Box 4033,
Herzliya
4614001, Israel
(Address of principal
executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Form 20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes
¨
No
x
If “Yes” is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-
N/A
Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. dated March 17, 2014 is hereby incorporated by reference into the registration statements on
Form S-8 and Form F-3 (File No. 333-148085, File No. 333-148754, File No. 333-154795 and File No. 333-194338) filed by XTL Biopharmaceuticals
Ltd. with the Securities and Exchange Commission on December 14, 2007, January 18, 2008, October 28, 2008, and March 5, 2014, respectively.
Re: Results of Extraordinary General
Meeting
Herzliya, Israel, March 17, 2014
-
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) (the “
Company
”) hereby announces the results of the Extraordinary
General Meeting of shareholders of the Company (“
EGM
”), held today, Monday, March 17, 2014, in Ramat Gan, Israel.
At the EGM, the proposal set forth in XTL’s announcement dated February 3, 2014 sent in connection with the EGM was
approved
by
the required majority of shareholders. The resolution was as follows:
Approval of Mr. Joshua Levine's
Employment Terms as Chief Executive Officer ("CEO"), Including Grant of 1,500,000 Non-Marketable, Listed Options, Exercisable
into Company Shares
In accordance with the resolution of the
Company’s Compensation Committee and Board of Directors dated January 30, 2014, the shareholders of the Company hereby approve
the terms of an employment agreement between the Company and Mr. Joshua Levine, pursuant to which Mr. Levine will serve as the
Company's CEO in a fulltime position.
The
terms of Mr. Levine’s employment agreement were summarized in a Form 6-K filed by the Company with the Securities and Exchange
Commission on February 3, 2014 which is incorporated herein by reference.
About XTL Biopharmaceuticals Ltd. (“XTL”)
XTL
Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition and development of pharmaceutical products for
the treatment of unmet clinical needs. XTL is focused on late stage clinical development of drugs for the treatment of lupus, multiple
myeloma and schizophrenia.
XTL
is a public company traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel-Aviv Stock Exchange (TASE: XTL). XTL shares
are included in the following indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Bluetech-50.
Contact:
Investor Relations, XTL Biopharmaceuticals
Ltd.
Tel: +972 9 955 7080, Email: ir@xtlbio.com,
www.xtlbio.com
Cautionary Statement
Some of the statements included in this
Form 6-K may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
XTL BIOPHARMACEUTICALS LTD.
|
|
|
|
|
|
|
|
|
|
Date: March 17, 2014
|
By:
|
/s/ Josh Levine
|
|
|
Josh Levine
|
|
|
Chief Executive Officer
|
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024